Co-Founder of THYTECH
Thytech
Thytech develops off-the-shelf regulatory T cell therapies, specifically thyTreg™ cells purified from the thymus gland, to restore immune balance in patients with serious immunological and inflammatory disorders. These therapies aim to prevent graft rejection in heart transplant infants and address life-threatening immune hyperactivation in COVID patients.
- Biotechnology
Updated 23 months ago
Funding
Raised to date
$380.7KRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Patients with immunological and inflammatory disorders often experience immune system imbalances that can lead to graft rejection after organ transplantation or life-threatening hyperactivation in response to infections. Current treatments are limited in their ability to restore immune balance effectively and can be difficult to access.
Solution
Thytech develops off-the-shelf regulatory T cell (Treg) therapies, called thyTreg™, derived from the thymus gland to address immune dysregulation. These therapies aim to re-establish immune homeostasis in patients with serious immunological and inflammatory conditions. Thytech's thyTreg cells are designed to prevent graft rejection, particularly in heart transplant infants, and to mitigate life-threatening immune hyperactivation, such as in severe COVID-19 cases. By utilizing allogeneic thyTreg sourcing combined with large-scale manufacturing, Thytech aims to provide readily available, off-the-shelf products to improve patient access to advanced immunotherapies.
Target Audience
The primary target audience includes patients with immunological and inflammatory disorders, specifically those undergoing organ transplantation or experiencing immune hyperactivation, as well as the healthcare providers who treat them.
Features
- First-in-class thyTreg™ therapies utilizing regulatory T cells purified directly from the thymus gland.
- Designed to treat and prevent serious imbalances of the immune system underlying acute and chronic conditions.
- Allogeneic potential of thyTreg cells may evade recognition by the patient’s immune system.
- Large-scale manufacturing processes to enable off-the-shelf availability and improved patient access.
- Potential application in a range of conditions, from transplant rejection to autoimmune diseases, severe inflammation, and neurodegenerative disorders.